应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
LEGN 传奇生物
休市中 05-29 16:00:00 EDT
27.16
-1.10
-3.89%
盘后
27.59
+0.43
+1.58%
19:59 EDT
最高
28.49
最低
26.52
成交量
245.22万
今开
28.26
昨收
28.26
日振幅
6.95%
总市值
50.45亿
流通市值
22.10亿
总股本
1.86亿
成交额
6,644万
换手率
3.01%
流通股本
8,138万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
港股异动 | 金斯瑞生物科技(01548)涨超5% 近日联营传奇生物多项研究成果于2026年ASCO年会发布
智通财经 · 05-27
港股异动 | 金斯瑞生物科技(01548)涨超5% 近日联营传奇生物多项研究成果于2026年ASCO年会发布
传奇生物(LEGN)盘中上涨1.71% 机构指Carvykti为多发性骨髓瘤领域同类最佳CAR-T疗法
金吾财讯 · 05-14
传奇生物(LEGN)盘中上涨1.71% 机构指Carvykti为多发性骨髓瘤领域同类最佳CAR-T疗法
港股异动 | 金斯瑞生物科技(01548)涨超5% 联营传奇生物一季度亏损收窄、CARVYKTI®净销售额增六成
智通财经 · 05-13
港股异动 | 金斯瑞生物科技(01548)涨超5% 联营传奇生物一季度亏损收窄、CARVYKTI®净销售额增六成
传奇生物公布截至2026年3月31日现金、现金等价物及定期存款达8.346亿美元
美股速递 · 05-12
传奇生物公布截至2026年3月31日现金、现金等价物及定期存款达8.346亿美元
传奇生物Q1 2026财报前瞻：CARVYKTI销售额预计约5.97亿美元
环球市场播报 · 05-11
传奇生物Q1 2026财报前瞻：CARVYKTI销售额预计约5.97亿美元
财报前瞻｜传奇生物本季度营收预计同比增58.58%，机构观点偏积极
财报Agent · 05-05
财报前瞻｜传奇生物本季度营收预计同比增58.58%，机构观点偏积极
股价5日拉升逾40%，礼来的70亿美元豪赌让市场看清低估的传奇生物(LEGN.US)？
智通财经 · 04-22
股价5日拉升逾40%，礼来的70亿美元豪赌让市场看清低估的传奇生物(LEGN.US)？
港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄
智通财经 · 03-17
港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄
【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元
金吾财讯 · 03-12
【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元
传奇生物CAR-T销售放量，盈利拐点将至下的喜与忧
21世纪经济报道 · 03-10
传奇生物CAR-T销售放量，盈利拐点将至下的喜与忧
财报前瞻｜传奇生物营收预计增71.50%，市场观点偏正面
财报Agent · 03-03
财报前瞻｜传奇生物营收预计增71.50%，市场观点偏正面
吉利德78亿美元全面收购Arcellx公司获得BCMA-CAR T疗法
药企市值评估 · 02-27
吉利德78亿美元全面收购Arcellx公司获得BCMA-CAR T疗法
传奇生物盘中异动 快速上涨16.83%
市场透视 · 02-23
传奇生物盘中异动 快速上涨16.83%
金斯瑞生物科技：传奇生物任命孟建革为董事
财中社 · 01-25
金斯瑞生物科技：传奇生物任命孟建革为董事
金斯瑞生物科技(01548)：孟建革获委任为传奇生物科技董事
智通财经 · 01-23
金斯瑞生物科技(01548)：孟建革获委任为传奇生物科技董事
终于有国产CAR-T企业快要扭亏了！传奇生物预计今年实现盈利
第一财经 · 01-22
终于有国产CAR-T企业快要扭亏了！传奇生物预计今年实现盈利
港股异动 | 金斯瑞生物科技(01548)跌超7% 联营传奇生物隔夜股价大跌逾11%
智通财经 · 01-22
港股异动 | 金斯瑞生物科技(01548)跌超7% 联营传奇生物隔夜股价大跌逾11%
前传奇生物副总裁潘琦加盟水木分子，出任生物医药首席科学家
新浪科技 · 01-09
前传奇生物副总裁潘琦加盟水木分子，出任生物医药首席科学家
股价半年即“腰斩”，传奇生物(LEGN.US)挖出的是估值陷阱还是黄金坑？
智通财经 · 01-07
股价半年即“腰斩”，传奇生物(LEGN.US)挖出的是估值陷阱还是黄金坑？
体内CAR-T赛道白热化：盘点国内19家核心企业管线全景图
求实药社 · 2025-12-18
体内CAR-T赛道白热化：盘点国内19家核心企业管线全景图
加载更多
公司概况
公司名称：
传奇生物
所属市场：
NASDAQ
上市日期：
--
主营业务：
传奇生物科技有限公司是一家全球性的临床级生物制药公司，致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。
发行价格：
--
{"stockData":{"symbol":"LEGN","market":"US","secType":"STK","nameCN":"传奇生物","latestPrice":27.16,"timestamp":1780084800000,"preClose":28.26,"halted":0,"volume":2452180,"hourTrading":{"tag":"盘后","latestPrice":27.59,"preClose":27.16,"latestTime":"19:59 EDT","volume":103488,"amount":2810869.8131,"timestamp":1780099166223,"change":0.43,"changeRate":0.015832,"amplitude":0.015832},"delay":0,"changeRate":-0.038924274593064453,"floatShares":81382003,"shares":185739791,"eps":-1.380412,"marketStatus":"休市中","change":-1.1,"latestTime":"05-29 16:00:00 EDT","open":28.26,"high":28.485,"low":26.52,"amount":66441478.699159995,"amplitude":0.069533,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.380412,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"adrRate":2,"listingDate":1591329600000,"exchange":"NASDAQ","adjPreClose":28.26,"preHourTrading":{"tag":"盘前","latestPrice":28.29,"preClose":28.26,"latestTime":"09:28 EDT","volume":1277,"amount":36977.931929,"timestamp":1780061280041,"change":0.03,"changeRate":0.001062,"amplitude":0.025124},"postHourTrading":{"tag":"盘后","latestPrice":27.59,"preClose":27.16,"latestTime":"19:59 EDT","volume":103488,"amount":2810869.8131,"timestamp":1780099166223,"change":0.43,"changeRate":0.015832,"amplitude":0.015832},"volumeRatio":1.543137274862104,"impliedVol":0.7899,"impliedVolPercentile":0.9562},"requestUrl":"/m/hq/s/LEGN","defaultTab":"news","newsList":[{"id":"2638527636","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 近日联营传奇生物多项研究成果于2026年ASCO年会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2638527636","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638527636?lang=zh_cn&edition=full","pubTime":"2026-05-27 09:57","pubTimestamp":1779847023,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技涨超5%，截至发稿，涨5.35%，报13.98港元，成交额5063.58万港元。消息面上，近日，金斯瑞生物科技发布公告，公司联营公司传奇生物科技股份有限公司已于2026年5月21日向美国证券交易委员会提交6-K表格并发布新闻稿，宣布在2026年美国临床肿瘤学会年会上发表多项研究成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","LEGN","VXUS","BK1141","BK1583","BK1576","BK4585","BK4588","BK4139","HK0000320264.USD","HK0000320223.HKD","01548","HK0000306701.USD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635574510","title":"传奇生物(LEGN)盘中上涨1.71% 机构指Carvykti为多发性骨髓瘤领域同类最佳CAR-T疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2635574510","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635574510?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:21","pubTimestamp":1778768489,"startTime":"0","endTime":"0","summary":"金吾财讯 | 传奇生物 盘中走高，截至发稿，报29.18美元，涨幅1.71%，成交额1524.93万美元。消息面上，RBC Capital Marketsu研究认为，传奇生物报告了Carvykti在第一季度的稳健表现，同时市场关注点正逐渐转向体内管线项目，预计未来几个月将有潜在更新，并在2026年之前取得更多的临床进展。分析师表示：“我们将Carvykti视为多发性骨髓瘤领域的同类最佳CAR-T疗法”，并补充称该疗法有望在2026年实现销售额达到$27.5亿，并在销售峰值时达到$80亿。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300469","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","BK4022","BK4588","BK4585","BK4505","CAR","BK4139","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635227658","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 联营传奇生物一季度亏损收窄、CARVYKTI®净销售额增六成","url":"https://stock-news.laohu8.com/highlight/detail?id=2635227658","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635227658?lang=zh_cn&edition=full","pubTime":"2026-05-13 09:34","pubTimestamp":1778636055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)涨超5%，截至发稿，涨5.03%，报15.23港元，成交额2969.6万港元。消息面上，金斯瑞生物科技联营传奇生物隔夜股价大涨超10%。传奇生物昨日公布了2026年第一季度未经审计的财务业绩及公司主要重点，与2025年第一季度相比，CARVYKTI®在2026年第一季度的净销售额增长62%，达到约5.97亿美元。其中美国市场净销售额增长36%，美国以外的市场净销售额增长222%。此外，公司截至2026年3月31日止三个月的净亏损收窄至5430万美元，而去年同期净亏损为1.010亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","01548","HK0000320264.USD","VXUS","HK0000320223.HKD","BK1141","BK4505","BK4139","LEGN","BK1576","BK4585","BK4588","HK0000306701.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176686384","title":"传奇生物公布截至2026年3月31日现金、现金等价物及定期存款达8.346亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176686384","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176686384?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583704,"startTime":"0","endTime":"0","summary":"传奇生物近日披露了其最新的财务状况。截至2026年3月31日，该公司持有的现金、现金等价物以及定期存款总额达到了8.346亿美元。\n这一数据展现了公司在特定时间点的财务实力与流动性水平。充足的现金储备为公司的研发活动、业务拓展及日常运营提供了坚实的资金保障。在生物科技领域，持续且大量的资金投入对于推进管线项目、应对市场挑战至关重要。因此，这笔可观的资金头寸无疑为公司的长期战略发展奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","BK4139","LEGN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634923334","title":"传奇生物Q1 2026财报前瞻：CARVYKTI销售额预计约5.97亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634923334","media":"环球市场播报","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634923334?lang=zh_cn&edition=full","pubTime":"2026-05-11 23:22","pubTimestamp":1778512920,"startTime":"0","endTime":"0","summary":"传奇生物将于5月12日周二盘前发布2026年第一季度财报，市场普遍关注其核心产品CARVYKTI的销售表现及公司盈利能力进展。根据已公布的初步数据，CARVYKTI第一季度净贸易销售额约为5.97亿美元。 CARVYKTI的销售增长仍是本季最大看点。尽管第一季度通常受季节性因素影响，但CAR-T疗法的需求依然强劲，此前公布的约5.97亿美元初步数据远超市场预期。此外，公司将在财报发布后举行电话会议，管理层对全年业绩指引及CAR-T竞争格局的看法备受关注。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-11/doc-inhxpxwx1741655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143439572","title":"财报前瞻｜传奇生物本季度营收预计同比增58.58%，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1143439572","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143439572?lang=zh_cn&edition=full","pubTime":"2026-05-05 08:47","pubTimestamp":1777942061,"startTime":"0","endTime":"0","summary":"传奇生物将于2026年05月12日发布新财季业绩，市场聚焦收入高增长与利润修复节奏。一致预期显示，本季度公司营收预计为3.07亿美元，同比增长58.58%；预计调整后每股收益为-0.02美元，同比增长90.53%；预计息税前利润为-324.34万美元，同比增长95.45%，若无法获取毛利率、净利润或净利率的预测数据则不展示。发展前景最大现有业务仍集中在“许可和协作”，上季度实现收入10.29亿美元，同比增长未披露，但结构性贡献显著，显示现金流与业绩韧性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜传奇生物本季度营收预计同比增58.58%，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629604010","title":"股价5日拉升逾40%，礼来的70亿美元豪赌让市场看清低估的传奇生物(LEGN.US)？","url":"https://stock-news.laohu8.com/highlight/detail?id=2629604010","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629604010?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:57","pubTimestamp":1776823046,"startTime":"0","endTime":"0","summary":"强劲的业绩兑现显然成为传奇生物股价的强心剂，带动传奇生物股价在4月14日和15日连续拉升。但相比亮眼业绩的助推，礼来4月20日宣布以最高70亿美元总对价收购Kelonia的消息带来的市场情绪波动似乎才是此轮传奇生物股价大幅拉升的关键催化剂。在可评估的5名患者中，ORR达100%，CR达80%。然而在这种背景下，传奇生物截至今年4月17日的市值仅39.16亿美元，仅比此次礼来向Kelonia支付的首付款高不到7亿美元，离该交易总对价70亿美元相差甚远。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2324357040.USD","SG9999015978.USD","LU0234572021.USD","LU2471134952.CNY","LU1551013342.USD","IE00BK4W5M84.HKD","LU0256863902.USD","LU2750360997.AUD","LU0823434583.USD","LU1917777945.USD","LU2271345857.HKD","IE00B4R5TH58.HKD","IE00B7KXQ091.USD","SG9999014906.USD","SG9999014898.SGD","LU0203201768.USD","LU2028103732.USD","SG9999017495.SGD","LU0943347566.SGD","LU2168564495.EUR","LU1069344957.HKD","LU2211815571.USD","LU2089283258.USD","LU2168564222.USD","LU1983299246.USD","IE0002141913.USD","LU0432979614.USD","LU0061475181.USD","LU1623119135.USD","LLII","LU1720051108.HKD","SG9999015945.SGD","LU1057294990.SGD","LU0158827948.USD","LU2357305700.SGD","LU0786609619.USD","LU2491049909.HKD","LU0133085943.USD","IE00BFTCPJ56.SGD","LU1093756325.SGD","ELIS","LLYZ","LU0417517546.SGD","LU0683600562.USD","LU2213496289.HKD","LU2552382132.HKD","LU1551013425.SGD","LU0708995401.HKD","LU2468319806.SGD","SG9999015952.SGD","LU2063271972.USD","BK4533","LU0882574139.USD","LU2896262040.SGD","GB00BDT5M118.USD","LU1988902786.USD","IE00BJJMRX11.SGD","LU2087625088.SGD","LU2417539215.USD","SG9999001176.USD","LU0316494557.USD","LU0006306889.USD","LU0323591593.USD","LU1127390331.HKD","LU2089984988.USD","LU2471134879.HKD","LU2237443382.USD","LU1267930730.SGD","LU0109391861.USD","LU2552382215.SGD","LU0353189680.USD","IE0004445015.USD","LU2462157665.USD","LU1280957306.USD","LU1145028129.USD","LU0114720955.EUR","LU0096364046.USD","SGXZ99366536.SGD","IE00BJLML261.HKD","LU2456880835.USD","LU0058720904.USD","LU1868837300.USD","LU2471134523.USD","LU2360106947.USD","IE00B775H168.HKD","LU1093756168.USD","LU1989771016.USD","SG9999013999.USD","LU0354030438.USD","IE00BJJMRY28.SGD","LU2756315318.SGD","LU0820562030.AUD","BK4516","LU2108987350.USD","IE0004445239.USD","LU2756315664.SGD","LU2106854487.HKD","SGXZ51526630.SGD","LU2491050071.SGD","BK4505","LU0203202063.USD","LU0823416689.USD","LU1291159041.SGD","LU1061106388.HKD","LU2237443895.HKD","SG9999018865.SGD","BK4534","LU1804176565.USD","LU0882574055.USD","BK4581","LU0320765992.SGD","LU0689472784.USD","IE00B1BXHZ80.USD","IE00BJJMRZ35.SGD","LU1868836914.USD","LU1868837136.USD","LU1720051017.SGD","LU2023250504.SGD","LU0820561909.HKD","LU0320765059.SGD","LU1629891620.HKD","LU1868836591.USD","LU2746668974.SGD","LU2237443622.USD","IE0001KFT4U8.USD","LU0210536198.USD","IE00B4JS1V06.HKD","LU0471298777.SGD","LU0238689110.USD","LU0466842654.USD","LEGN","LU0266013472.USD","LU2168563687.JPY","LU2750360641.GBP","SG9999001176.SGD","LU2471134796.USD","LU1712237335.SGD","LU0353189763.USD","LU0122379950.USD","LU2089284900.SGD","LU0158827781.USD","LU1064131342.USD","IE00BKDWB100.SGD","LU0094547139.USD","LU0385154629.USD","LU2237443549.SGD","LU2361045086.USD","LU0964807845.USD","LU0256863811.USD","IE00BFSS7M15.SGD","IE00BKPKM429.USD","LU1814569148.SGD","LU0097036916.USD","LU1548497426.USD","LU2264538146.SGD","IE00BJT1NW94.SGD","IE0005OL40V9.USD","IE00BN29S564.USD","LU0787776722.HKD","SGXZ57979304.SGD","LU2168564065.EUR","LU0354030511.USD","LU2023251221.USD","LU2237443978.SGD","SG9999015986.USD","IE0009355771.USD","IE00B1XK9C88.USD","IE00BFSS8Q28.SGD","LU1974910355.USD","LU2023250330.USD","LU0823434740.USD","LU0106261372.USD","LU0456855351.SGD","LU2361044865.SGD","BK4007","LU2237438978.USD","BK4585","SG9999014914.USD","BK4139","LU1868836757.USD","LU0471298694.HKD","LU1232071149.USD","LU2552382058.USD","LU1323610961.USD","IE00BK4W5L77.USD","LU2168564149.EUR","LU2112291526.USD","LU2746668461.USD","BK4588","LU0889565916.HKD","LLYX","LU1023059063.AUD","LU0079474960.USD","LU0672654240.SGD","LU2111349929.HKD","LU1035775433.USD","LU2491050154.USD","SGXZ81514606.USD","LU0225283273.USD","LU0198837287.USD","LU2237443465.HKD","LU0289739699.SGD","LU2602419157.SGD","LU0640476718.USD","IE00BWXC8680.SGD","LU2461242641.AUD","LU0820561818.USD","SG9999014880.SGD","SGXZ31699556.SGD","BK4599","IE00B2B36J28.USD","LU2236285917.USD","LU0109394709.USD","LU2361044949.HKD","SG9999018857.SGD","LU1366192091.USD","ELIL","LU2265009873.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620412370","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2620412370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620412370?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:15","pubTimestamp":1773717332,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技涨超5%，截至发稿，涨3.24%，报66.95港元，成交额6281.35万港元。消息面上，3月15日，金斯瑞生物科技发布截至2025年12月31日止年度业绩，该集团期内取得收益9.6亿美元，同比增加61.4%；母公司拥有人应占亏损5.33亿美元，同比盈转亏；每股基本亏损24.58美分。华泰证券指出，金斯瑞生物科技2025年业绩符合预期，各主要业务板块展现稳健增长或扭亏态势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548","BK4585","HK0000306701.USD","BK1583","HK0000320264.USD","BK4505","VXUS","BK4139","BK1576","BK1141","LEGN","HK0000306685.HKD","BK4588","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618718200","title":"【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618718200","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618718200?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:07","pubTimestamp":1773306468,"startTime":"0","endTime":"0","summary":"金吾财讯 | 有报道引述消息人士称，金斯瑞生物科技(01548)联营公司传奇生物计划今年在香港上市，集资3亿至4亿美元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK4588","BK1576","HK0000306701.USD","HK0000320223.HKD","BK4505","BK4585","01548","HK0000320264.USD","HK0000306685.HKD","LEGN","BK1583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618956896","title":"传奇生物CAR-T销售放量，盈利拐点将至下的喜与忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2618956896","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618956896?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:25","pubTimestamp":1773149131,"startTime":"0","endTime":"0","summary":"3月10日，传奇生物（NASDAQ:LEGN）发布了截至2025年12月31日的第四季度及全年财务业绩。这份成绩单不仅标志着公司核心产品CARVYKTI?（西达基奥仑赛）首次实现产品线盈利，也展现出国产CAR-T出海标杆从“烧钱扩张”向“自我造血”转型的关键一跃。财报显示，CARVYKTI?在2025年第四季度实现净销售额约5.55亿美元，全年销售额达18.87亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667731683.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667731683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4588","LEGN","BK4230","BK4505","BK4022","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177311064","title":"财报前瞻｜传奇生物营收预计增71.50%，市场观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1177311064","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177311064?lang=zh_cn&edition=full","pubTime":"2026-03-03 10:13","pubTimestamp":1772503992,"startTime":"0","endTime":"0","summary":"传奇生物将于2026年03月10日发布最新季度财报，市场普遍聚焦许可协作收入的延续性、亏损收窄与核心产品商业化节奏对单季表现的拉动。市场一致预期本季度公司营收约3.07亿美元，同比增长71.50%；调整后每股收益预计为-0.11，同比增长64.00%；息税前利润预计为-2,018.35万美元，同比增长75.75%，当前未见关于毛利率、净利润或净利率的权威一致预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜传奇生物营收预计增71.50%，市场观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614852749","title":"吉利德78亿美元全面收购Arcellx公司获得BCMA-CAR T疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2614852749","media":"药企市值评估","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614852749?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:46","pubTimestamp":1772196399,"startTime":"0","endTime":"0","summary":"近日，吉利德宣布以78亿美元估值全面收购其2022年就牵手合作的伙伴公司Arcellx，消息宣布当天Arcellx股价大涨近80%。以下文字写于2024年11月，标题《再论Arcellx公司的BCMA-CAR T疗法》我又仔细研读了Arcellx公司2023年年报，发现这个公司在技术上还是有一些新东西的。目前传奇生物是70亿美元市值出头，Arcellx甚至有追平的趋势。以下文字写于2023年11月，标题《Arcellx公司的BCMA-CART似乎数据不错，但是临床进展太滞后了》近日，","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227213733a4379541&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227213733a4379541&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","BK4505","BK4139","BK4022","BK4585","BK4588","BK4230","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613712209","title":"传奇生物盘中异动 快速上涨16.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613712209?lang=zh_cn&edition=full","pubTime":"2026-02-23 22:31","pubTimestamp":1771857100,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日22时31分，传奇生物股票出现波动，股价大幅上涨16.83%。截至发稿，该股报21.17美元/股，成交量82.1899万股，换手率0.45%，振幅2.32%。传奇生物股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Arcellx, Inc.、Vanda Pharmaceuticals Inc.、传奇生物涨幅较大，Psyence Biomedical Ltd.、Cardio Diagnostics Holdings Inc.、Fortress Biotech, Inc.较为活跃，换手率分别为174.88%、32.56%、25.59%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc.、Camp4 Therapeutics Corporation、Aspire Biopharma Holdings, Inc.，振幅分别为11.46%、9.68%、9.50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223140a4bf4bfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223140a4bf4bfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4505","LEGN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606925154","title":"金斯瑞生物科技：传奇生物任命孟建革为董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2606925154","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606925154?lang=zh_cn&edition=full","pubTime":"2026-01-25 16:08","pubTimestamp":1769328532,"startTime":"0","endTime":"0","summary":"1月23日，金斯瑞生物科技（01548）发布公告，宣布其联营公司传奇生物科技股份有限公司任命孟建革为董事，任期至2026年周年股东大会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601253629921412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4505","LEGN","BK4139","BK4588","HK0000320223.HKD","BK1583","01548","BK1576","HK0000306701.USD","BK1141","BK4585","HK0000320264.USD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605405308","title":"金斯瑞生物科技(01548)：孟建革获委任为传奇生物科技董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2605405308","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605405308?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:13","pubTimestamp":1769177619,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，自2026年1月20日起，传奇生物科技股份有限公司(“传奇”，为公司联营公司，其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)董事会任命孟建革先生为董事，初始任期至传奇2026年周年股东大会为止。孟建革先生获委任接替朱力博士于传奇董事会的职务，朱力博士于生效日期辞任该职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","BK4585","BK1583","01548","BK1576","HK0000306701.USD","LEGN","BK4139","BK1141","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605446971","title":"终于有国产CAR-T企业快要扭亏了！传奇生物预计今年实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2605446971","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605446971?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:08","pubTimestamp":1769072934,"startTime":"0","endTime":"0","summary":"在绝大多数国产CAR-T企业苦于商业化挣扎之际，率先出海的传奇生物（LEGN.NS）业绩快要“上岸”了。传奇生物的CAR-T药物合作方强生于当地时间1月21日公布的财报显示，Carvykti（西达基奥仑赛）在2025年实现收入18.88亿美元，较上年同期（9.63亿美元）增长95.9%。西达基奥仑赛是一款用于治疗复发或难治性多发性骨髓瘤的细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601223627442037.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627442037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4230","BK4139","LEGN","BK4022","CAR","BK4588","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605455188","title":"港股异动 | 金斯瑞生物科技(01548)跌超7% 联营传奇生物隔夜股价大跌逾11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605455188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605455188?lang=zh_cn&edition=full","pubTime":"2026-01-22 10:58","pubTimestamp":1769050689,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)跌超7%，截至发稿，跌6.98%，报13.07港元，成交额1.3亿港元。消息面上，金斯瑞生物科技联营传奇生物隔夜股价大跌逾11%。1月21日晚，金斯瑞生物科技公布，传奇生物披露CARVYKTI于截至去年12月31日止第四季度贸易销售净额约5.55亿美元。该集团指，贸易销售净额乃基于杨森向传奇提供的资料，传奇与该集团均未独立核实该销售数字的准确性。据了解，CARVYKTI前三季度实现销售额13.32亿美元，其中第三季度销售额为5.24亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","BK1610","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","BK4585","BK1583","01548","BK1576","HK0000306701.USD","LEGN","BK4139","BK1141","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602031467","title":"前传奇生物副总裁潘琦加盟水木分子，出任生物医药首席科学家","url":"https://stock-news.laohu8.com/highlight/detail?id=2602031467","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602031467?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:39","pubTimestamp":1767919140,"startTime":"0","endTime":"0","summary":"新浪科技讯 1月9日上午消息，新浪科技独家获悉，原传奇生物研发副总裁潘琦已加入清华大学智能产业院 孵化成立的AI生物医药企业“水木分子”，将出任生物医药首席科学家全面负责公司生物医药与ChatDD科研战略、研发体系建设、AI 药物管线推进及全球合作布局等工作。 据知情人士对新浪科技透露，加入水木分子前，潘琦近期曾任职于美国知名AI肿瘤生物技术公司Pathos，任癌症生物学高级副总裁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tob/2026-01-09/doc-inhfsfzv3104115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4588","BK4585","BK4505","161726","399441","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601879976","title":"股价半年即“腰斩”，传奇生物(LEGN.US)挖出的是估值陷阱还是黄金坑？","url":"https://stock-news.laohu8.com/highlight/detail?id=2601879976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601879976?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:47","pubTimestamp":1767779266,"startTime":"0","endTime":"0","summary":"1月6日，传奇生物股价在开盘5分钟内出现一波下探，虽然后续出现大幅反弹带动日内最高涨幅突破6%，但那波下探却将传奇生物在2026年的股价最低点定格在了20.21美元。但在11月12日，传奇生物在当日股价下跌2.67%的情况下出现前期明显的成交量放。目前来看，传奇生物的营收主要由许可收入和合作收入两部分构成。并且对比Carvykti在34个月的随访数据，Tec-Dara联合治疗组已经超越其的84.6%响应率和76.4%的OS率，且在残余病灶阴性率上与Carvykti保持一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IAU","BK4588","1OZmain","159831","159934","SGCmain","BK4505","MGCmain","BK4139","DUST","GCmain","QOmain","GDX","LEGN","518880","SGUmain","NUGT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2592838922","title":"体内CAR-T赛道白热化：盘点国内19家核心企业管线全景图","url":"https://stock-news.laohu8.com/highlight/detail?id=2592838922","media":"求实药社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592838922?lang=zh_cn&edition=full","pubTime":"2025-12-18 12:02","pubTimestamp":1766030559,"startTime":"0","endTime":"0","summary":"跨国药企重磅加注，国内Biotech加速推进，体内CAR-T已成细胞治疗领域的热门赛道。这项颠覆性技术旨在解决传统CAR-T高成本、长周期的痛点，并进一步拓展血液瘤、实体瘤及自免疾病适应症。纵观国内研发格局，体内CAR-T正呈现出“技术路线多元化”与“临床验证加速化”的双重特征。从进展来看，IIT已成为当前验证体内CAR-T安全性与有效性的主战场。2025年3月完成首例患者给药，进入临床阶段，是国内较早进入体内CAR临床阶段的企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218134128a459f8ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218134128a459f8ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1583","01952","LEGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.legendbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0752},{"period":"1month","weight":0.1928},{"period":"3month","weight":0.4295},{"period":"6month","weight":-0.0198},{"period":"1year","weight":-0.0625},{"period":"ytd","weight":0.2493}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"传奇生物科技有限公司是一家全球性的临床级生物制药公司，致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.047546},{"month":2,"riseRate":0.5,"avgChangeRate":0.01776},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.03136},{"month":4,"riseRate":0.833333,"avgChangeRate":0.112839},{"month":5,"riseRate":0.5,"avgChangeRate":0.032168},{"month":6,"riseRate":1,"avgChangeRate":0.150366},{"month":7,"riseRate":0.666667,"avgChangeRate":0.033873},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.05555},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.023313},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.000245},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.020911},{"month":12,"riseRate":0,"avgChangeRate":-0.105244}],"exchange":"NASDAQ","name":"传奇生物","nameEN":"Legend Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"传奇生物,LEGN,传奇生物股票,传奇生物股票老虎,传奇生物股票老虎国际,传奇生物行情,传奇生物股票行情,传奇生物股价,传奇生物股市,传奇生物股票价格,传奇生物股票交易,传奇生物股票购买,传奇生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}